Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan-human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients with Advanced Non-small-cell Lung Cancer

Overview

Journal J Clin Oncol

Specialty Oncology

Date 2012 Jul 4

PMID 22753918

Citations 109

Authors

Suresh S Ramalingam

Fiona Blackhall

Maciej Krzakowski

Carlos H Barrios

Keunchil Park

Isabel Bover

Dae Seog Heo

Rafael Rosell

Denis C Talbot

Richard Frank

Stephen P Letrent

Ana Ruiz-Garcia

Ian Taylor

Jane Q Liang

Alicyn K Campbell

Joseph OConnell

Michael Boyer

Affiliations

Soon will be listed here.

Abstract

Purpose: This randomized, open-label trial compared dacomitinib (PF-00299804), an irreversible inhibitor of human epidermal growth factor receptors (EGFR)/HER1, HER2, and HER4, with erlotinib, a reversible EGFR inhibitor, in patients with advanced non-small-cell lung cancer (NSCLC).

Patients And Methods: Patients with NSCLC, Eastern Cooperative Oncology Group performance status 0 to 2, no prior HER-directed therapy, and one/two prior chemotherapy regimens received dacomitinib 45 mg or erlotinib 150 mg once daily.

Results: One hundred eighty-eight patients were randomly assigned. Treatment arms were balanced for most clinical and molecular characteristics. Median progression-free survival (PFS; primary end point) was 2.86 months for patients treated with dacomitinib and 1.91 months for patients treated with erlotinib (hazard ratio [HR] = 0.66; 95% CI, 0.47 to 0.91; two-sided P = .012); in patients with KRAS wild-type tumors, median PFS was 3.71 months for patients treated with dacomitinib and 1.91 months for patients treated with erlotinib (HR = 0.55; 95% CI, 0.35 to 0.85; two-sided P = .006); and in patients with KRAS wild-type/EGFR wild-type tumors, median PFS was 2.21 months for patients treated with dacomitinib and 1.84 months for patients treated with erlotinib (HR = 0.61; 95% CI, 0.37 to 0.99; two-sided P = .043). Median overall survival was 9.53 months for patients treated with dacomitinib and 7.44 months for patients treated with erlotinib (HR = 0.80; 95% CI, 0.56 to 1.13; two-sided P = .205). Adverse event-related discontinuations were uncommon in both arms. Common treatment-related adverse events were dermatologic and gastrointestinal, predominantly grade 1 to 2, and more frequent with dacomitinib.

Conclusion: Dacomitinib demonstrated significantly improved PFS versus erlotinib, with acceptable toxicity. PFS benefit was observed in most clinical and molecular subsets, notably KRAS wild-type/EGFR any status, KRAS wild-type/EGFR wild-type, and EGFR mutants.

Citing Articles

Is Autophagy Targeting a Valid Adjuvant Strategy in Conjunction with Tyrosine Kinase Inhibitors?.

Elshazly A, Xu J, Melhem N, Abdulnaby A, Elzahed A, Saleh T Cancers (Basel). 2024; 16(17).

PMID: 39272847 PMC: 11394573. DOI: 10.3390/cancers16172989.

A Review of the Molecular Determinants of Therapeutic Response in Non-Small Cell Lung Cancer Brain Metastases.

Boldig C, Boldig K, Mokhtari S, Etame A Int J Mol Sci. 2024; 25(13).

PMID: 39000069 PMC: 11241836. DOI: 10.3390/ijms25136961.

Effects of H2-Receptor Antagonists on the Exposure of Dacomitinib.

Liu J, Lin S, Huynh A, Tan W Pharmaceutics. 2024; 16(1).

PMID: 38258127 PMC: 10819565. DOI: 10.3390/pharmaceutics16010118.

Prevalence of mutations in common tumour types in Northern England and comparable utility of national and international Trial Finders.

Rae S, Plummer E, Fitzgerald L, Hogarth L, Bridgewood A, Brown-Schofield L J Cancer Res Clin Oncol. 2023; 149(18):16355-16363.

PMID: 37702806 PMC: 10645649. DOI: 10.1007/s00432-023-05365-y.

Optimizing the Treatment for Advanced Non-Small-Cell Lung Cancer with Mutated Epidermal Growth Factor Receptor in Low-Income Countries: A Review.

Alali M, Saifo M J Immunother Precis Oncol. 2023; 6(3):140-149.

PMID: 37637235 PMC: 10448734. DOI: 10.36401/JIPO-22-29.

References

Ouwerkerk J, Boers-Doets C . Best practices in the management of toxicities related to anti-EGFR agents for metastatic colorectal cancer. Eur J Oncol Nurs. 2010; 14(4):337-49. DOI: 10.1016/j.ejon.2010.03.004. View

Hynes N, Lane H . ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005; 5(5):341-54. DOI: 10.1038/nrc1609. View

Gonzales A, Hook K, Althaus I, Ellis P, Trachet E, Delaney A . Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor. Mol Cancer Ther. 2008; 7(7):1880-9. DOI: 10.1158/1535-7163.MCT-07-2232. View

Kluter S, Simard J, Rode H, Grutter C, Pawar V, Raaijmakers H . Characterization of irreversible kinase inhibitors by directly detecting covalent bond formation: a tool for dissecting kinase drug resistance. Chembiochem. 2010; 11(18):2557-66. DOI: 10.1002/cbic.201000352. View

Yarden Y, Sliwkowski M . Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001; 2(2):127-37. DOI: 10.1038/35052073. View

Zhou C, Wu Y, Chen G, Feng J, Liu X, Wang C . Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2011; 12(8):735-42. DOI: 10.1016/S1470-2045(11)70184-X. View

Roberts P, Stinchcombe T, Der C, Socinski M . Personalized medicine in non-small-cell lung cancer: is KRAS a useful marker in selecting patients for epidermal growth factor receptor-targeted therapy?. J Clin Oncol. 2010; 28(31):4769-77. DOI: 10.1200/JCO.2009.27.4365. View

Engelman J, Zejnullahu K, Gale C, Lifshits E, Gonzales A, Shimamura T . PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res. 2007; 67(24):11924-32. DOI: 10.1158/0008-5472.CAN-07-1885. View

Li T, Perez-Soler R . Skin toxicities associated with epidermal growth factor receptor inhibitors. Target Oncol. 2009; 4(2):107-19. DOI: 10.1007/s11523-009-0114-0. View

10.

Therasse P, Arbuck S, Eisenhauer E, Wanders J, Kaplan R, Rubinstein L . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92(3):205-16. DOI: 10.1093/jnci/92.3.205. View

11.

Peppercorn J, Smith T, Helft P, Debono D, Berry S, Wollins D . American society of clinical oncology statement: toward individualized care for patients with advanced cancer. J Clin Oncol. 2011; 29(6):755-60. DOI: 10.1200/JCO.2010.33.1744. View

12.

Mok T, Wu Y, Thongprasert S, Yang C, Chu D, Saijo N . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009; 361(10):947-57. DOI: 10.1056/NEJMoa0810699. View

13.

Shepherd F, Pereira J, Ciuleanu T, Tan E, Hirsh V, Thongprasert S . Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005; 353(2):123-32. DOI: 10.1056/NEJMoa050753. View

14.

Bronte G, Rizzo S, La Paglia L, Adamo V, Siragusa S, Ficorella C . Driver mutations and differential sensitivity to targeted therapies: a new approach to the treatment of lung adenocarcinoma. Cancer Treat Rev. 2010; 36 Suppl 3:S21-9. DOI: 10.1016/S0305-7372(10)70016-5. View

15.

Barraclough H, Simms L, Govindan R . Biostatistics primer: what a clinician ought to know: hazard ratios. J Thorac Oncol. 2011; 6(6):978-82. DOI: 10.1097/JTO.0b013e31821b10ab. View

16.

Bell D, Lynch T, Haserlat S, Harris P, Okimoto R, Brannigan B . Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol. 2005; 23(31):8081-92. DOI: 10.1200/JCO.2005.02.7078. View

17.

Pao W, Wang T, Riely G, Miller V, Pan Q, Ladanyi M . KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med. 2005; 2(1):e17. PMC: 545207. DOI: 10.1371/journal.pmed.0020017. View

18.

Shepherd F . Maintenance therapy comes of age for non-small-cell lung cancer, but at what cost?. J Clin Oncol. 2011; 29(31):4068-70. DOI: 10.1200/JCO.2011.37.8349. View

19.

Hartmann J, Haap M, Kopp H, Lipp H . Tyrosine kinase inhibitors - a review on pharmacology, metabolism and side effects. Curr Drug Metab. 2009; 10(5):470-81. DOI: 10.2174/138920009788897975. View

20.

Janne P, Boss D, Camidge D, Britten C, Engelman J, Garon E . Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res. 2011; 17(5):1131-9. PMC: 3048920. DOI: 10.1158/1078-0432.CCR-10-1220. View